• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Viruses, Vol. 15, Pages 105: Topoisomerase II as a Novel Antiviral Target against Panarenaviral Diseases
ro Yasuda Although many arenaviruses cause severe diseases with high fatality rates each year, treatment options are limited to off-label use of ribavirin, and a Food and Drug Administration (FDA)-approved vaccine is not available. To identify novel therapeutic candidates against arenaviral diseases, an RNA polymerase I-driven minigenome (MG) expression system for Lassa virus (LASV) was developed and optimized for high-throughput screening (HTS). Using this system, we screened 2595 FDA-approved compounds for inhibitors of LASV genome replication and identified multiple compounds including pixantrone maleate, a topoisom...
Source: Viruses - December 30, 2022 Category: Virology Authors: Tosin Oladipo Afowowe Yasuteru Sakurai Shuzo Urata Vahid Rajabali Zadeh Jiro Yasuda Tags: Article Source Type: research

Junin Virus Activates p38 MAPK and HSP27 Upon Entry
Junín virus (JUNV), a New World arenavirus, is a rodent-borne virus and the causative agent of Argentine hemorrhagic fever. Humans become infected through exposure to rodent host secreta and excreta and the resulting infection can lead to an acute inflammatory disease with significant morbidity and mortality. Little is understood about the molecular pathogenesis of arenavirus hemorrhagic fever infections. We utilized Reverse Phase Protein Microarrays (RPPA) to compare global alterations in the host proteome following infection with an attenuated vaccine strain, Candid#1 (CD1), and the most parental virulent strain, XJ13, ...
Source: Frontiers in cellular and infection microbiology - April 7, 2022 Category: Microbiology Source Type: research

Lifecycle modelling systems support inosine monophosphate dehydrogenase (IMPDH) as a pro-viral factor and antiviral target for New World arenaviruses
Publication date: Available online 19 July 2018Source: Antiviral ResearchAuthor(s): Eric C. Dunham, Anne Leske, Kyle Shifflett, Ari Watt, Heinz Feldmann, Thomas Hoenen, Allison GrosethAbstractInfection with Junín virus (JUNV) is currently being effectively managed in the endemic region using a combination of targeted vaccination and plasma therapy. However, the long-term sustainability of plasma therapy is unclear and similar resources are not available for other New World arenaviruses. As a result, there has been renewed interest regarding the potential of drug-based therapies. To facilitate work on this issue, we presen...
Source: Antiviral Therapy - July 20, 2018 Category: Virology Source Type: research

Lifecycle modelling systems support inosine monophosphate dehydrogenase (IMPDH) as a pro-viral factor and antiviral target for New World arenaviruses.
Abstract Infection with Junín virus (JUNV) is currently being effectively managed in the endemic region using a combination of targeted vaccination and plasma therapy. However, the long-term sustainability of plasma therapy is unclear and similar resources are not available for other New World arenaviruses. As a result, there has been renewed interest regarding the potential of drug-based therapies. To facilitate work on this issue, we present the establishment and subsequent optimization of a JUNV minigenome system to a degree suitable for high-throughput miniaturization, thereby providing a screening platform f...
Source: Antiviral Research - July 19, 2018 Category: Virology Authors: Dunham EC, Leske A, Shifflett K, Watt A, Feldmann H, Hoenen T, Groseth A Tags: Antiviral Res Source Type: research